NL16-1_0329
|
|
- のぶあき いのら
- 5 years ago
- Views:
Transcription
1 No.16-1 March JAMTTC News Letter Japanese Association for Molecular Target Therapy of Cancer TEL: ext.5413 FAX:
2 ...1 JAMTTC AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2011 San Francisco) JAMTTC-JSGDT
3 FDA2005Drug-Diagnostics Co-Development JAMTTC3 TR (JSGDT) JAMTTCJSGDT TR7TR TR JAMTTC March,
4 JAMTTC No No JAMTTC Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
5 PDFWORD TEL: ext FAX: jamttc@jfcr.or.jp March,
6 PDFWORD TEL: ext FAX: jamttc@jfcr.or.jp 4 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
7 () 3 () () () March,
8 Year in Review Year in Review 1 Year in Review TEL: , jamttc16@umin.ac.jp 6 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
9 March,
10 News DNA ATRA 3019Trastuzumab LapatinibHer2GefitinibErlotinibCetuximabPanitumumabLapatinib Epidermal growth factor receptoregfrimatinibbcr-ablc-kit 2011CrizotinibRuxolitinibALKJAK SorafenibSunitinibPazopanib VandetanibAxitinibImatinib Bcr-AblDasatinibNilotinib mtortemsirolimuseverolimus BRAF V600EVemurafenib2011 DNA (DNMT)AzacitidineDecitabine (HDAC)VorinostatRomidepsin4 CD20RituximabCD52Alemtuzumab (VEGF)BevacizumabRANKLDenosumabCTLA-4 IplimumabBortezomib 20121HedgehogHhVismodegib News LetterNo.15-2RuxolitinibAxitinibVismodegib3 : 8 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
11 March,
12 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2011 San Francisco) EORTCNCI AACR 1 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics PKPDPhaseII , Treatment of Premalignant ConditionsClinical Trial Paradigms in the Era of Novel Therapies2Educational Session13Opening Plenary SessionNovel Clinical Paradigms in Personalized Medicine Lessons from the BRAF-Targeted Therapy of MelanomaPlenary Session14 Developing Novel Validated Preclinical ModelsMechanistic-Based ImmunotherapyPlenary Session PI3K Concurrent Session 15The Epigenome as a Therapeutic Target Targeting Tumor Stroma InteractionPlenary SessionDNA Concurrent Session16 Rational Cancer Drug Development for Targeted Drugs: The Interface Between Industry, Academia, and RegulatorsTargeting Tumor MetabolismPlenary Session Phase IPK&PD BRAFmTOR/PI3K plenary session Phase Phase disease-based drug screening 10 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
13 AACR-NCI-EORTCEORTC-NCI-ASCO J AMTTCJSGDT AACR-NCI-EORTC EORTC-NCI-ASCO2 AACR-NCI-EORTC EORTC-NCI-ASCO Molecular Markers in Cancer AACR-NCI-EORTC Vemurafenib (Zelboraf )Crizotinib (Xalkori ) FDA2005 Drug-Diagnostic Co-Development JAMTTCJSGDT 2008 Phase I microenvironmentimmunologymetastasis/invasion stem cellnew assay March,
14 tumor metabolism EORTC-NCI-ASCO5 AACR-NCI-EORTC Molecular Markers in Cancer PDF PDF 2 EORTC-NCI-ASCO AACR-NCI-EORTC EORTC-NCI-ASCO 12 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
15 (JAMTTC)(JSGDT) JAMTTCJSGDT2011 JAMTTC JSGDT FDA JAMTTCJSGDT March,
16 I I I-1 I-2 II II III 14 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
17 March,
18 16 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
19 17 March, 2012 PD PD 2 PD PD Go/NoGo PD PD PD 1 PD mtorps6 I-1 PD
20 RatainPD PD Go/NoGo PD Bolen Bolen ubiquitin-like proteins: UBLsNEDD8E1 NEDD8-activating enzymenae MLN4924MLN4924 NEDD8NAE I bulk MLN4924E3 NEDD8cullin-RING CRLs Cdt1Nrf2CRL MLN4924 Cdt1Nrf2 I NAEPD NAE DNAre-replication >4NDNA Chk1-3 PD BolenNEDD8UBLs CRLNAEPD NEDD8UBLs 18 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
21 E3 PD Go/NoGo PD March,
22 I Drug- Diagnostic Co-development 1 20 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
23 8 (MD) MD 2008 MD 2008 NEDO MD proof of concept(poc) (eind) PET MD MD 2 in vivo PET, MRI (Always ON) Activatable March,
24 PET, MRIcm mm Herceptin in vitroin vivo Herceptin ( gamma-glutamultranspeptidase, GGT) 3 ALKoma Hunting ALK ALKEML4-ALK multiplex RT-PCR ALK (iaep) (IHC)EML4-ALK IHC EML4-ALK ALK 5-RACEKLC- ALKALK ALK ALK 3 22 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
25 II 1 / DNARNAEU (ICH)E15 2FDA Valid Biomarkers Known Valid Biomarkers Probable Valid Biomarkers March,
26 Exploratory Biomarkers outocome AHRQ EGAPPEvidence-Based Review of Genomic Tests 3UGT1A1 genotypinginsufficient evidence Centers for Disease Control and Prevention, CDC ACCE wheel 4Analytic Validity Clinical Validity Clinical Utility [Ethical, legal, and social implications(elsi)]4 ACCEACCE OECDCDC JCCLS Tentative Guideline 4 24 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
27 4 () Pharmacogenomics Working Group SNP (UGT1A1CYP2C19CYP3A5 CYP2C9VKORC1) k-ras SNP March,
28 ( ) (JCCLS) ( ( ( ) JCCLS (201012) home-brew 26 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
29 )(PGx) UGT1A1 () ()PGx PGx PGx PGx UGT1A14 PGx PGx PGx PGx March,
30 4 Molecular Targets and Cancer Therapeutics PGx PGx K-Ras PGx PGx CoDx 28 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
31 codevelopment March,
32 30 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
33 31 March, 2012
34 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
35 March,
36 34 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
37 March,
38 36 Japanese Association for Molecular Target Therapy of Cancer News Letter No.16-1
39
40
41
42
NL10
Information September, 2006 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.10 September, 2006 3 2006 4 Japanese Association for Molecular Target Therapy of Cancer News Letter
More informationNL09
Information September, 2005 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.9 September, 2005 3 2005 4 Japanese Association for Molecular Target Therapy of Cancer News Letter
More information14-2JAMTTCNL0913F
JAMTTC News Letter No.14-2 Sept. 2010 http://jamttc.umin.jp Japanese Association for Molecular Target Therapy of Cancer information September, 2010 1 News 2 Japanese Association for Molecular Target Therapy
More informationNL11
information September, 2007 1 2 Japanese Association for Molecular Target Therapy of Cancer News Letter No.11 September, 2007 3 2007 4 Japanese Association for Molecular Target Therapy of Cancer News Letter
More informationNews Letter No.17 2008.1.1
17 No. P 2 P 4 P 6 P 8 P10 P11 P12 P15 News Letter No.17 2008.1.1 News Letter No.17 2008.1.1 4 News Letter No.17 2008.1. News Letter No.17 2008.1. 5 News Letter No.17 2008.1.1 6 News Letter No.17 2008.1.1
More informationuntitled
NEWS LETTER No.5 2006.12 1 No. 2006 2 2006/11/30 2006/11/30 2006/11/29 No. 2006 2006/11/29 2006/11/29 2006/11/28 3 No. 2006 4 No. 2006 2006/11/27 2006/11/27 2006/11/27 2006/11/27 5 No. 2006 2006/11/27
More informationVENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
More informationNEWS LETTER vol.40 01
NEWS LETTER vol.40 01 NEWS LETTER vol.40 02 03 NEWS LETTER vol.40 NEWS LETTER vol.40 04 05 NEWS LETTER vol.40 NEWS LETTER vol.40 06 NEWS LETTER vol.40 07 NEWS LETTER vol.40 08 09 NEWS LETTER vol.40 NEWS
More information1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
More information2018表紙.indd
8 57 60 3 11 2018 2 2018 2 3 1 ISBN 2 230 3 http:// www.unp.or.jp 1 412 2,000 320 2,000 352 1,600 268 1,800 1982 86 195 21 1987 978-4-930689-67-2 SDI 1989 978-4-8158-0116-8 1983 978-4-930689-08-5 1984
More information- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
More information2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
More information20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
More informationI? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
More informationスライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
More information2009年度 東京薬科大学 薬学部 授業計画
2009 2 234 Tokyo University of Pharmacy and Life Sciences since 880 Tokyo University of Pharmacy and Life Sciences Department of Clinical Pharmacy Men's Division Department of Clinical Applied Pharmacy
More informationindd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
More informationtitle
6580003 41822 0784535931 http://www.kabto-yama.ac.jp/hiroba/ 1 NEWS LETTER NO.26 ( ) 2 NEWS LETTERNO.26 3 NEWS LETTER NO.26 4 NEWS LETTERNO.26 5 NEWS LETTER NO.26 10 18 10 11 10 6 NEWS LETTER NO.26 7 NEWS
More informationFDAの 対 応 :Critical Path Initiative 2004 年 開 始 産 官 学 の 連 携 により 科 学 技 術 の 進 展 を 医 薬 品 開 発 につな げる 際 の 多 様 な 課 題 の 解 決 を 目 指 すプログラム 2006 年 有 効 性 及 び 安 全 性
資 料 3 個 別 化 医 療 コンパニオン 診 断 薬 を めぐる 規 制 動 向 平 成 25 年 1 月 30 日 医 薬 品 バイオ 製 品 合 同 専 門 部 会 医 薬 品 医 療 機 器 総 合 機 構 規 格 基 準 部 鹿 野 真 弓 FDAの 対 応 :Critical Path Initiative 2004 年 開 始 産 官 学 の 連 携 により 科 学 技 術 の 進
More information(2009) 1... / 1 ( ) / 1 ( ) / 1 ( ), 2 ( )
212009................................................ 2............................................ 115 (2009) 1... / 1 ( )........................................... 4 2... / 1 ( )......................................
More informationuntitled
CONTENTS 01 02-03 04-05 06-07 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 48-49 50-51 52 01 02 Mishima,Michiaki 03 04 05 06 07 09 10 11
More informationuntitled
19CRC/2009.8.8-9 T0 T1 T2 T3 T4 M0 N0 M1 19CRC 2009.8.8 1 2 N1 N2 N3 Stage 0 Stage I Stage IIA Stage IIB Stage IIIA Stage IIIB Stage IIIC Stage IV Tis 3 4 5 6 1 19CRC/2009.8.8-9 7 8 Subtype of Breast Cancer
More information56: Hands-on 4 Meet the Expert.
56:136 57 2016 28 5 18 21. 650-0046 6-9-1 650-0046 6-11-1 650-0046 6 10-1 2016 2 9 7 13 Hands-on 4 Meet the Expert. http://www.neurology-jp.org/sokaitiho/neuro2016/ 15,000 18,000 3,000 3,000 3,000 3,000
More informationcm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
More informationuntitled
Japanese Standards Association 2014 http://www.jsa.or.jp/kentei/qc/qc-top.asp
More informationRadix News Letter 48号
March 2007 48 Radix News Letter c o n t e n t s 2 Radix 8 Report 4 5 6 7 9 Radicle NEWS 10 12 Information 2 Radix News Letter 48 Radix News Letter 48 3 Report 4Radix News Letter 48 Report Radix News Letter
More informationGN151-200.doc
Good News No.151 Good News No.152 Good News No.153 Good News No.154 Good News No.155 Good News No.156 Good News No.157 Good News No.158 Good News No.159 CO2 Good News No.160 Good News No.161 Good
More informationNEDO
10 MRI 1 1 595% 5 IOR 100% MRI MRI MRI MRI MRI MRI 11 MRI 3 2 1 MRI 1 1.5 0.000005 100 5 MRI MRI MRI MRI MRI MRI MRI MRI MRI (1) MRI MRI 0.3 3 MRI 1 / (2) MRI MRI (3)MRI MRI 3 (4)MRI MRI MRI (5)MRI 2006
More informationMicrosoft Word - TIP2006-3-TGN doc
TIP 2006 3 Vol 21 No3 p21-24 TGN1412 I NPO 3 13 15 [1,2] I TGN1412 18 40 1 ICU 19 6 4 3 [3] The Medicines and Healthcare Products Regulatory Agency MHRA [2] TGN1412 TGN1412 CD28-SuperMAB T TGN1412 T superagonistic
More information24回日本エイズ学会誌1_ indd
10 ICAAP 11 24 9:40 10:10 1 B1F 1. 10 Myung-Hwan Cho 2. Zahid Hussein President of AIDS Society of Asia and the Pacific ASAP 11 24 13:10 15:40 1 B1F 1 13:10 13:55 PS1-1 ART in the Developing World: Progress
More informationNAVIGATION MD Consult MD Consult Home home Books Book List page Journals Journal Search page Drugs Drug Look-up:Drug UpdatesDrug Information News This
NAVIGATION...2 BOOKS...4 JOURNALS...5 DRUGS...8 NEWS...8 NEWS...9 CURRENT PRACTICE...10 PATIENT HANDOUTS...11 LEARNING CENTER...12 Search...13 My Folder...14 1 NAVIGATION MD Consult MD Consult Home home
More informationPowerPoint Presentation
第 14 回抗悪性腫瘍薬開発フォーラム個別化医療における薬剤と検査薬と開発に向けての課題 製薬企業より : CoDx どのように開発を進めていくか ~ 自社開発の経験から ~ アステラス製薬 ( 株 ) 臨床薬理部 竹下滋 本日の内容 1. 医薬品開発におけるバイオマーカーの臨床応用 2. 製薬会社における CoDx 開発の試み 個別化医療の推進 CoDx 開発を推進する体制の構築 3. 製薬会社における
More information44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
More informationuntitled
( ) 200133 3 3 3 3, 7 347 57 10 i ii iii -1- -2- -3- -4- 90011001700mm -5- 4.2 1991 73.5 44.4 7.4 10.5 10.5 7.4 W 3 H 2.25 H 2.25 7.4 51.8 140.6 88.8 268.8m 5,037.9m 2 2mm 16cm916cm 10.5 W 3 H 2.25 62.8
More information2 1
http://www.kikkoman.co.jp/ 2 1 21,646 11,219 5,275 17,350 6,056 20,983 2,777 10,793 4,327 10,125 10,739 128,391 359,906 119,975 392,611 59,993 202,727 18,557 1,401 4,052 4,045 5,702 5,852 2,378 103,445
More information14.08月号.indd
2014. no511 8 News 2014.8 News 2014.8 News 2014.8 News 2014.8 2014.8 2014.8 News 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 2014.8 1 2 3 4 5 6 7 8
More information15.03月号.indd
2015. no518 3 2015.3 2015.3 News 2015.3 2015.3 News News 2015.3 2015.3 2015.3 2015.3 2015.3 2015.3 2015.3 2015.3 2015.3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
More information15.06月号.indd
2015. no521 6 2015.6 News 2015.6 News News 2015.6 2015.6 News News 2015.6 News 2015.6 2015.6 2015.6 2015.6 2015.6 2015.6 2015.6 2015.6 2015.6 2015.6 2015.6 2015.6 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
More information中表紙
3 企業での FIH 試験導入の考え方 日本での規制面 実施施設での問題点 November 18, 2011 Shiro Akinaga, Ph.D. Development Division / Kyowa Hakko Kirin Co., Ltd. 1 Hallmarks of Cancer : Next Generation (Cell 144: 646 2011) Imatinib, Gefitinib,
More information特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More informationPubMed 1. CD-ROM MEDLINE MeSH PubMed 2. Automatic Term Mapping MeSH 3. Related Article 1 1. 2. MeSH Browser MeSH PreMEDLINE MeSH -2-
PubMed MEDLINE NLM 1879 Index Medicus 1960 MEDLARS Medical Literature Analysis and Retrieval System 1970 MEDLINE MEDlars online 1966 70 4,000 170 PubMed MEDLINE NLM National Center for Biotechnology Information
More informationi ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
More informationNo21Vol1.indd
( ): - PSA Shojiro Kano Head, Working Group of PSA Testing Standardization Committee (PSA) PSA PSA JCCLS PSA A PSA B PSA PSA Wang PSA FDA Hybritech Tandem-R PSA PSA PSA PSA - (ACT) - (AMG) ACT (PSA-ACT)
More informationuntitled
Japanese Proteomics Society 2010 kumamoto pref. kumamon#15752 日本プロテオーム学会 2015 年会 JHUPO 第13回大会 タンパク質がおりなす 生命システムの全体像を理解する プロテオミクスを基盤とした 生命科学研究の最前線と医療への応用 プログラム 抄録集 会期 2015 年 7月23日 24日 会場 くまもと森都心プラザ 年会長
More information<4F495341836A8385815B835832308EFC944E8B4C944F8D862E696E6464>
OITA INFORMATION SERVICE INDUSTRY ASSOCIATION CONTENTS 2009. 3 47 02 OITA INFORMATION SERVICE INDUSTRY ASSOCIATION NEWS 03 OITA INFORMATION SERVICE INDUSTRY ASSOCIATION 04 05 NEWS OITA INFORMATION SERVICE
More informationuntitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
More informationBN.j...[.X
Group News Letter NEWS 108-0075 2-16-2 9F http://www.bandainamco.co.jp/ No. 7 2007 March Management Eyes 2007 March No.7 Management Eyes BANDAI NAMCO NEWS Financial Data 2007 March No.7 News Topics BANDAI
More informationIonTorrentPGM_appnote_0319.indd
Ion PGM Heterogeneity * 1 * 1 * 2 * 2 * 2 * 2 * 2 * 1 *1 * 2 DNA DNA DNA ArcturusXT LCM Laser Capture Microdissection LCM A Workflow for Cancer Profiling Applied Biosystems ViiA7 PCR qpcr QC Assay Ion
More information2
1 2 (10 ) 900 800 200 20% 7732 ) 700 600 500 400 300 55.9 26.2 81.5 20 29 30.1 64.7 66.1 31.4 88.4 19.4 31.1 32 67.7 73.5 36.3 95.6 20.5 32.1 33.2 63.7 101.9 89.1 49.1 42.8 129.7 112.9 22.3 23.4 41.3 36.8
More information第79回_プログラム.indd
Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial
More information.T.C.Y._.E..
25 No.33 C O N T E N T S REVIEW 1 2 5 4 3 6 7 8 9 1 11 1, 1, 7,5 75 916,95 (121) 756,67 (15) 718,89 (13) 91,496 (169) 54,2 (179) 3,243 (75) 727,333 (129) 564,47 (112) 55,458 (11) 6,68,953 (18) 5,624,957
More information<4D F736F F F696E74202D20322D3591E63289F182AA82F F28A4A94AD8D8793AF C B E31318C8E313
第 2 回がん新薬開発合同シンポジュームポストゲノム時代の新薬開発を考える コンパニオン診断薬開発を巡る諸問題 ロシュ ダイアグノスティックス IVD 事業本部メディカルマーケティング部田澤義明 2012 年 11 月 16 日 Diagnostics Pharmaceuticals 1 本日の内容 個別化医療におけるコンパニオン診断薬 (CoDx) の役割 CoDx 開発に関するガイダンス案の概要とインパクト
More informationø ø Lessons Learned from the Worldwide Spread of Evidence-Based Medicine (EBM) Abstract Keywords Evidence-based Policies in Education: New Directions and Issues Abstract Keywords Contribution
More informationPowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
More informationuntitled
ORYZA POLYAMINE ORYZA POLYAMINE -P -PC -LC 1. Ver.1.0 MM ver. 1.0MM 1) Roseeuw D.I. et al., Epidermal keratinocytes actively maintain their intracellular polyamine levels. Cell Tissue Kinet. 16, 493-504
More informationニュースレター10-1.indd
The Japanese Society of Immunotoxicology 101192005 aaaa 12 2005172021 1-1-1 Tel. 03-5841-8205 / Dr. R.H. Pieters () "Immunotoxicology of therapeutics associated with allergy and autoimmunity" 2005 In
More informationDIALOG MEDLINE...1 BIOSIS PREVIEWS...7 DIOGENES: ADVERSE DRUG EVENTS DATABASE PHARMAPROJECTS...21 IMS R&D FOCUS...22 DATASTAR..
DIALOG 200304200403 MEDLINE...1 BIOSIS PREVIEWS...7 DIOGENES: ADVERSE DRUG EVENTS DATABASE...9...15 PHARMAPROJECTS...21 IMS R&D FOCUS...22 DATASTAR...23 http://database.g-search.or.jp 108-0022 Loop-X F
More informationサイトメトリー12-1.indd
Cell Growth Inhibition and Apoptosis in Cancer Cells Kazuki Omoteyama, Shoichi Inoue and Alaa-eldin Salah-eldin Department of Environmental Medicine and Informatics, Graduate School of Environmental Earth
More information